SCHEMBL427479

SCHEMBL427479

O=C(N1CCC(Cc2ccccc2)CC1)n1nnc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FAAH O00519 16/20 1.00
MGLL Q99685 16/20 1.00
KCNH2 Q12809 1/20 0.53
HRH3 Q9Y5N1 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL424377 0.88 FAAH (0.79) FAAHMGLL
SCHEMBL425491 0.86 FAAH (0.76) FAAHMGLL
SCHEMBL5641463 0.85 FAAH (0.74) FAAHMGLL
SCHEMBL425704 0.82 FAAH (0.70) FAAHMGLL
SCHEMBL5641853 0.82 FAAH (0.69) FAAHMGLL
SCHEMBL427655 0.82 FAAH (0.69) FAAHMGLL
SCHEMBL19357103 0.81 FAAH (0.81) FAAHMGLL
SCHEMBL425463 0.81 MGLL (0.68) FAAHMGLL
SCHEMBL5639585 0.81 FAAH (0.67) FAAHMGLL
SCHEMBL5641596 0.81 FAAH (0.67) FAAHMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-7208504-B2 Bicyclic inhibitors of hormone sensitive lipase SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-04-24 US disclosed
US-7208504-B2 Bicyclic inhibitors of hormone sensitive lipase SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-04-24 US disclosed
US-7208504-B2 Bicyclic inhibitors of hormone sensitive lipase SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-04-24 US disclosed
EP-1554259-B1 NOVEL BICYCLIC INHIBITORS OF HORMONE SENSITIVE LIPASE SANOFI AVENTIS DEUTSCHLAND (DE) 2006-12-27 EP disclosed
EP-1554259-A1 NOVEL BICYCLIC INHIBITORS OF HORMONE SENSITIVE LIPASE Aventis Pharma Deutschland GmbH (DE) 2005-07-20 EP disclosed
US-20040127484-A1 Novel bicyclic inhibitors of hormone sensitive lipase AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-07-01 US disclosed
WO-2004035550-A1 NOVEL BICYCLIC INHIBITORS OF HORMONE SENSITIVE LIPASE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885MGLL 11/4885KCNH2 1739/4885
US-20040127484-A1 Novel bicyclic inhibitors of hormone sensitive lipase LIPE, PNLIP, CEL FAAH 144/4885MGLL 20/4885KCNH2 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.